Inhibiting RRM2 to enhance the anticancer activity of chemotherapy

被引：95

作者：

Zhan, Yaqiong ^{[1
]}

Jiang, Lushun ^{[1
]}

Jin, Xuehang ^{[1
]}

Ying, Shuaibing ^{[1
]}

Wu, Zhe ^{[1
]}

Wang, Li ^{[2
]}

Yu, Wei ^{[1
]}

Tong, Jiepeng ^{[1
]}

Zhang, Li ^{[1
]}

Lou, Yan ^{[1
]}

Qiu, Yunqing ^{[1
]}

机构：

[1] Zhejiang Univ, Coll Med,State Key Lab Diag & Treatment Infect Di, Affiliated Hosp 1,Collaborat Innovat Ctr Diag & T, Natl Clin Res Ctr Infect Dis,Zhejiang Prov Key La, 79 QingChun Rd, Hangzhou 310000, Zhejiang, Peoples R China

[2] Zhejiang Univ, Coll Med, Affiliated Hosp 1, Dept Rehabil Med, 79 QingChun Rd, Hangzhou 310000, Zhejiang, Peoples R China

来源：

BIOMEDICINE & PHARMACOTHERAPY | 2021年 / 133卷

基金：

中国国家自然科学基金;

关键词：

Ribonucleotide reductase subunit M2; Chemotherapy; Chemoresistance; Small interfering RNA; RRM2; inhibitors; Kinase inhibitors; RIBONUCLEOTIDE REDUCTASE M2; 3-AMINOPYRIDINE-2-CARBOXALDEHYDE THIOSEMICARBAZONE 3-AP; ANTISENSE OLIGONUCLEOTIDE GTI-2040; MESSENGER-RNA EXPRESSION; BREAST-CANCER CELLS; PHASE-I TRIAL; NF-KAPPA-B; PANCREATIC-CANCER; DNA-DAMAGE; SUBUNIT M2;

D O I：

10.1016/j.biopha.2020.110996

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

1001 ;

摘要：

RRM2, the small subunit of ribonucleotide reductase, is identified as a tumor promotor and therapeutic target. It is common to see the overexpression of RRM2 in chemo-resistant cancer cells and patients. RRM2 mediates the resistance of many chemotherapeutic drugs and could become the predictor for chemosensitivity and prognosis. Therefore, inhibition of RRM2 may be an effective means to enhance the anticancer activity of chemotherapy. This review tries to discuss the mechanisms of RRM2 overexpression and the role of RRM2 in resistance to chemotherapy. Additionally, we compile the studies on small interfering RNA targets RRM2, RRM2 inhibitors, kinase inhibitors, and other ways that could overcome the resistance of chemotherapy or exert synergistic anticancer activity with chemotherapy through the expression inhibition or the enzyme inactivation of RRM2.

引用

页数：8

共 97 条

[1]

[Anonymous], 1985, J BIOL CHEM, V260, P9114

[2] Role of NF-κB and Akt/PI3K in the resistance of pancreatic carcinoma cell lines against gemcitabine-induced cell death [J].

Arlt, A ;

Gehrz, A ;

Müerköster, S ;

Vorndamm, J ;

Kruse, ML ;

Fölsch, UR ;

Schäfer, H .

ONCOGENE, 2003, 22 (21) :3243-3251

[3] Ribonucleotide reductase and cancer: biological mechanisms and targeted therapies [J].

Aye, Y. ;

Li, M. ;

Long, M. J. C. ;

Weiss, R. S. .

ONCOGENE, 2015, 34 (16) :2011-2021

[4] Determinants of resistance to 2′,2′-difluorodeoxycytidine (gemcitabine) [J].

Bergman, AM ;

Pinedo, HM ;

Peters, GJ .

DRUG RESISTANCE UPDATES, 2002, 5 (01) :19-33

[5] Differential Processing of let-7a Precursors Influences RRM2 Expression and Chemosensitivity in Pancreatic Cancer: Role of LIN-28 and SET Oncoprotein [J].

Bhutia, Yangzom Doma ;

Hung, Sau Wai ;

Krentz, Madeline ;

Patel, Dimal ;

Lovin, Dylan ;

Manoharan, Radhika ;

Thomson, J. Michael ;

Govindarajan, Rajgopal .

PLOS ONE, 2013, 8 (01)

[6] Gemcitabine resistance in pancreatic ductal adenocarcinoma [J].

Binenbaum, Yoav ;

Na'ara, Shorook ;

Gil, Ziv .

DRUG RESISTANCE UPDATES, 2015, 23 :55-68

[7] Tumor BRCA1, RRM1 and RRM2 mRNA Expression Levels and Clinical Response to First-Line Gemcitabine plus Docetaxel in Non-Small-Cell Lung Cancer Patients [J].

Boukovinas, Ioannis ;

Papadaki, Chara ;

Mendez, Pedro ;

Taron, Miquel ;

Mavroudis, Dimitris ;

Koutsopoulos, Anastasios ;

Sanchez-Ronco, Maria ;

Javier Sanchez, Jose ;

Trypaki, Maria ;

Staphopoulos, Eustathios ;

Georgoulias, Vassilis ;

Rosell, Rafael ;

Souglakos, John .

PLOS ONE, 2008, 3 (11)

[8] The role of gemcitabine in the treatment of other tumours [J].

Carmichael, J .

BRITISH JOURNAL OF CANCER, 1998, 78 (Suppl 3) :21-25

[9] DHS (trans-4,4′-dihydroxystilbene) suppresses DNA replication and tumor growth by inhibiting RRM2 (ribonucleotide reductase regulatory subunit M2) [J].

Chen, Chi-Wei ;

Li, Yongming ;

Hu, Shuya ;

Zhou, Wei ;

Meng, Yunxiao ;

Li, Zongzhu ;

Zhang, Yi ;

Sun, Jing ;

Bob, Zhou ;

DePamphilis, Melvin L. ;

Yen, Yun ;

Han, Zhiyong ;

Zhu, Wenge .

ONCOGENE, 2019, 38 (13) :2364-2379

[10] Gemcitabine resistance mediated by ribonucleotide reductase M2 in lung squamous cell carcinoma is reversed by GW8510 through autophagy induction [J].

Chen, Ping ;

Wu, Jian-Nong ;

Shu, Yang ;

Jiang, He-Guo ;

Zhao, Xiao-Hui ;

Qian, Hai ;

Chen, Kang ;

Lan, Ting ;

Chen, Chen-Guo ;

Li, Jian .

CLINICAL SCIENCE, 2018, 132 (13) :1417-1433

← 1 2 3 4 5 6 7 8 9 10 →